Brentuximab Vedotin After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects and best way to give brentuximab vedotin and
to see how well it works after donor stem cell transplant in treating patients with
hematologic malignancies. Monoclonal antibodies, such as brentuximab vedotin, can block
cancer growth in different ways. Some block the ability of cancer to grow and spread. Others
find cancer cells and help kill them or carry cancer-killing substances to them. Monoclonal
antibodies may kill cancer cells that are left after donor stem cell transplant.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Fred Hutchinson Cancer Research Center
Collaborators:
National Cancer Institute (NCI) Seagen Inc. Seattle Genetics, Inc.